Creo Medical Group (LON:CREO) Issues Earnings Results

Creo Medical Group (LON:CREO) posted its quarterly earnings data on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%.

Creo Medical Group Price Performance

Shares of LON:CREO traded down GBX 0.13 during midday trading on Friday, hitting GBX 9.67. The company had a trading volume of 2,207,440 shares, compared to its average volume of 794,158. Creo Medical Group has a twelve month low of GBX 9.50 and a twelve month high of GBX 18.50. The stock has a market cap of £46.96 million, a price-to-earnings ratio of 9.67 and a beta of 1.56. The company has a debt-to-equity ratio of 8.09, a current ratio of 2.79 and a quick ratio of 2.19. The business’s 50-day simple moving average is GBX 12.62 and its 200-day simple moving average is GBX 12.82.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 target price on shares of Creo Medical Group in a research report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.